Company Filing History:
3 out of 5,094 
3 out of 1,745 
3 out of 870 
Years Active: 2018-2021
Title: The Innovative Contributions of Jean-Baptiste Guillerme
Introduction
Jean-Baptiste Guillerme is a notable inventor based in Nantes, France. He has made significant contributions to the field of cancer therapy through his innovative work with genetically modified viruses. With a total of 3 patents to his name, Guillerme's research focuses on harnessing the power of modified infectious agents to combat malignant tumors.
Latest Patents
One of Guillerme's latest patents involves the use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties, known as the MV-deltaC virus. This invention pertains to a modified strain of the live-attenuated measles virus, where the gene encoding the viral accessory C protein has been knocked out. The primary application of this invention is in the treatment of malignant tumors or cancer conditions, as well as the preparation of agents or compositions for such therapeutic interventions.
Career Highlights
Throughout his career, Guillerme has worked with prestigious research institutions, including the Centre National de la Recherche Scientifique and the Institut National de la Santé et de la Recherche Médicale. His work has been pivotal in advancing the understanding and application of viral therapies in oncology.
Collaborations
Guillerme has collaborated with esteemed colleagues in his field, including Frédéric Tangy and Marc Gregoire. These partnerships have further enriched his research and contributed to the development of innovative cancer treatment strategies.
Conclusion
Jean-Baptiste Guillerme's contributions to cancer therapy through his inventive use of genetically modified viruses highlight the potential of innovative approaches in medicine. His work continues to inspire advancements in the fight against cancer.